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REVIEW ARTICLE OPEN
Asthma exacerbations and worsenings in patients aged 1–75
years with add-on tiotropium treatment
J. Mark FitzGerald1✉, Eckard Hamelmann2,3, Huib A. M. Kerstjens 4,5 and Roland Buhl6
This review explores the effect of tiotropium Respimat® add-on therapy on asthma exacerbations and worsenings, adverse events
(AEs) related to exacerbations and symptoms and any effects on seasonality across the 10 UniTinA-asthma® clinical trials
comprising over 6000 patients. When added on to inhaled corticosteroids ± additional therapies, tiotropium significantly reduced
the risk of exacerbations and worsenings in adults with symptomatic severe asthma and provided a non-significant improvement in
worsenings in adults with symptomatic moderate and mild asthma, which was significant for patients with moderate asthma
receiving tiotropium 2.5 µg once daily vs. placebo. Trials in paediatric patients were not powered to assess exacerbations or
worsenings, but when AEs related to asthma exacerbations and symptoms were grouped into a composite endpoint and pooled,
tiotropium improved outcomes vs. placebo (rate ratio 0.76; 95% confidence interval 0.63, 0.93). The reduction in exacerbations with
tiotropium is apparent across all patients during the observed seasonal peaks of these events.
npj Primary Care Respiratory Medicine           (2020) 30:38 ; https://doi.org/10.1038/s41533-020-00193-w
INTRODUCTION
Despite established treatment guidelines for asthma, and reports
suggesting that it is possible for most patients to achieve control
of their illness, many patients remain symptomatic and have poor
disease control1,2. Poorly controlled asthma is associated with
functional limitations, pulmonary function loss, reduced quality of
life and increased risk of exacerbations1. Asthma exacerbations
represent an acute change in a patient’s usual symptoms and lung
function, and are caused by multiple triggers3. Symptoms include
shortness of breath, coughing, wheezing and chest tightness, each
of which can be a frightening experience for the patient4,5. The
prevention of exacerbations and worsenings, or preventing the
future risk of exacerbations and worsenings, is one of the main
treatment goals of current asthma guidelines3,6. Powering a trial to
assess asthma exacerbations requires a sufficient study duration
and adequate patient numbers—in particular, those who are
unstable and at risk of experiencing exacerbations. Assuming that
asthma worsenings are an indicator of asthma exacerbation risk,
then asthma worsenings could be used as an alternative study
endpoint which has clinical relevance. This could allow for studies
of shorter duration and smaller sample sizes7–9.
DEFINING ASTHMA EXACERBATIONS AND WORSENINGS
Although definitions have been proposed by groups including the
Global Initiative for Asthma (GINA) and the American Thoracic
Society/European Respiratory Society (Table 1), there is no clear
consensus definition for asthma ‘exacerbations’10,11. It is also
noted that there is no consensus definition of worsenings, with
literature definitions generally including increased use of short-
acting β2-agonists (SABAs), peak expiratory flow (PEF) changes
and increased day- and night-time symptoms9. Patients them-
selves may not understand or be aware of the terms ‘exacerbation’
or ‘worsening’. There has therefore been a suggestion that despite
having variable meanings, the use of the terms ‘attack’, ‘episode’
or ‘flare-up’ may facilitate patient and care provider recognition of
a deterioration of asthma control and the need to seek additional
controller options3,12.
The lack of a single definition for either asthma exacerbations or
worsenings makes it difficult to compare outcomes across
multiple clinical trials10,13. However, this is possible with the
UniTinA-asthma® clinical trial database of ten randomised, double-
blind, placebo-controlled, parallel-group trials lasting between
12 weeks and 1 year in duration, which all used the same
definitions. This allows us to review the effect of tiotropium
Respimat® add-on therapy on episodes of asthma exacerbations
and worsenings, as well as adverse events (AEs) related to
exacerbations and symptoms, over a large patient population.
Tiotropium Respimat® has been shown to be an efficacious and
well-tolerated add-on treatment to inhaled corticosteroid (ICS)
therapy with or without additional controllers, with comparable
safety and efficacy to long-acting β2-agonists (LABAs)
14–22. A
systematic review and meta-analysis comparing the efficacy and
safety of tiotropium with that of LABAs as add-on to ICS in
patients with uncontrolled persistent asthma aged 12 years and
older reported comparable improvements in clinical outcomes22.
Similarly, in paediatric patients aged 4–17 years with asthma, a
recent literature review of LABAs, leukotriene receptor antagonists
(LTRAs) and tiotropium reported that tiotropium and LABAs have
similar efficacy and provide greater improvements in lung
function than LTRAs as add-on to ICS. All three add-on therapies
had comparable safety profiles23.
Here, we collate and review the published literature on the
effect of add-on tiotropium treatment on asthma exacerbations
and worsenings in patients aged 1–75 years. We also look at any
effect of tiotropium on seasonality of asthma exacerbations and
worsenings14–21 (Supplementary Figure 1).
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TREATMENT FOR ASTHMA EXACERBATIONS AND
WORSENINGS
GINA recommends that controller medication is adjusted in a
stepwise approach—stepped up if control is not achieved and
stepped down once good asthma control has been achieved for at
least 3 months—in order to find the lowest appropriate treatment
for the patient that controls both symptoms and exacerbations
(Fig. 1)3,24.
The long-acting muscarinic antagonist tiotropium Respimat® is
indicated in the EU as add-on maintenance bronchodilator
treatment in patients aged 6 years and older with severe asthma
who experienced one or more severe asthma exacerbation in the
preceding year25. In the United States, it is indicated for the long-
term, once-daily maintenance treatment of asthma in patients
aged 6 years and older26. It has been evaluated as add-on to at
least ICS therapy in >6000 patients aged 6–75 years with
symptomatic asthma, and aged 1–5 years with persistent
asthmatic symptoms, in the comprehensive Phase II and III
UniTinA-asthma® clinical trial programme. Within the individual
trials, it has been shown to be an efficacious and well-tolerated
add-on treatment to ICS therapy with or without additional
controllers14–21.
EXACERBATIONS AS AN ENDPOINT IN PAEDIATRIC STUDIES
Paediatric patients are a vulnerable population, with exacerbations
being a particular concern. However, powering a placebo-
controlled trial to assess asthma exacerbations as a primary
endpoint in paediatric patients can present ethical considera-
tions27. If exacerbations are anticipated, not providing the best
proven standard of care exposes paediatric patients to unneces-
sary risk27,28. The trial length required to gather sufficient
exacerbations data is also problematic for children, especially for
those receiving a placebo. Paediatric patients receiving a placebo
may be more likely to withdraw from a trial than those receiving
the active treatment due to experiencing exacerbations28.
Furthermore, for many patients, the effect of a medication on
exacerbations may be a lower priority than its impact on more
frequently reported outcomes, such as asthma symptoms or lung
function. Subsequently, alternative endpoints may be preferable
when assessing the efficacy of asthma treatments in terms of
exacerbation risk reduction. Szefler et al.29 previously demon-
strated that using AEs related to exacerbations and symptoms as
endpoints was aligned to using exacerbations as an endpoint, and
that it was possible to detect treatment differences with AE
reporting when exacerbation data were not available.
SEASONALITY OF ASTHMA EXACERBATIONS AND
WORSENINGS
Although asthma exacerbations and worsenings may present
sporadically, they are often determined by seasons30,31. Peaks may
mirror patterns of allergen exposure and prevalence of respiratory
viral infections30,31.
As in adults, AEs related to asthma exacerbations and
symptoms in paediatric patients also display seasonal patterns.
However, these patterns differ from those seen in adults, with
paediatric patients more likely to experience exacerbations or
worsenings in the spring and autumn months32,33. The autumn
peak of exacerbations in children and adolescents is largely
attributed to an increased frequency of rhinovirus infections
among children returning to school following the summer
break34,35.
STUDIES INCLUDED WITHIN REVIEW
Tiotropium Respimat® has been evaluated as add-on to at least
ICS therapy in patients aged 6–75 years with symptomatic asthma
and 1–5 years with persistent asthmatic symptoms in the
comprehensive Phase II and III UniTinA-asthma clinical trial
programme that included >6000 patients (Table 2). We collated
previously published data from the ten UniTinA-asthma clinical
trials, to assess and discuss the effect of tiotropium Respimat®
add-on therapy on asthma exacerbations and worsenings, as well
as AEs related to exacerbations and symptoms, in patients aged
1–75 years. The clinical trial programme included two replicate
trials in adults with symptomatic severe asthma (PrimoTinA-
asthma [NCT00772538/NCT00776984])19, two replicate trials in
adults with symptomatic moderate asthma (MezzoTinA-asthma
[NCT01172808/NCT01172821])20 and one trial in adults with
Table 1. Definitions of asthma exacerbations and worsenings.
Definition GINA3 ATS/ERS13 Primo/Mezzo/GraziaTinA-asthma trials in
adult patients19–21 and Pensie/Ruba/Viva/




Episodes characterised by a progressive
increase in symptoms (e.g. shortness of
breath, cough, wheezing or chest
tightness) and a progressive decrease in
lung function that require a change in
the patient’s usual treatment
Moderate exacerbations: events that
include deterioration in symptoms or
lung function, or increased rescue
bronchodilator use lasting at least 2 days,
that require a temporary change in
treatment (with the exception of systemic
corticosteroids or hospitalisation)
Severe exacerbations: event that requires
use of systemic corticosteroids or an
increase from the patient’s usual stable
maintenance dose for at least 3 days, or
hospitalisation
An episode of progressive increase in ≥1
asthma symptom(s) (as compared with
usual day-to-day asthma symptoms), or a
decline of ≥30% in PEFa.m. for ≥2
consecutive days, requiring systemic
corticosteroids for ≥3 days
Asthma
worsenings
An episode of progressive increase in ≥1
asthma symptom(s) (as compared with
usual day-to-day asthma symptoms), or a
decline of ≥30% in PEFa.m. for ≥2
consecutive days
ATS American Thoracic Society, ERS European Respiratory Society, GINA Global Initiative for Asthma, PEFa.m. morning peak expiratory flow.
J Mark FitzGerald et al.
2













Fig. 1 GINA treatment recommendations for patients aged ≥12 years, 6–11 years and ≤5 years3. GINA treatment recommendations for
stepping up or stepping down of asthma controller and reliever therapy for the management of asthma for patients aged (a) ≥12 years, (b)
6–11 years and (c) ≤5 years. © 2020, Global Initiative for Asthma, reproduced with permission. FEV1 forced expiratory volume in 1s, GINA
Global Initiative for Asthma, HDM house dust mite, ICS inhaled corticosteroid, Ig immunoglobulin, IL interleukin, LABA long-acting β2-agonist,
LTRA leukotriene receptor antagonist, OCS oral corticosteroids, SABA short-acting β2-agonist, SLIT sublingual immunotherapy.
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symptomatic mild asthma (GraziaTinA-asthma [NCT01316380])21.
In adolescents (aged 12–17 years), there were two trials: one in
patients with symptomatic severe (PensieTinA-asthma
[NCT01277523])15 and one in patients with symptomatic moder-
ate asthma (RubaTinA-asthma [NCT01257230])14. Similarly, there
were two trials in children (aged 6–11 years): one in patients with
symptomatic severe (VivaTinA-asthma [NCT01634152])18 and one
in patients with symptomatic moderate asthma (CanoTinA-asthma
[NCT01634139])17. In children aged 1–5 years, there was one trial
in patients with persistent asthmatic symptoms (NinoTinA-asthma
[NCT01634113])16.
The two replicate PrimoTinA-asthma trials in adults with
symptomatic severe asthma, when pooled by the study investi-
gators, were the only trials powered to assess exacerbations, with
a primary predefined efficacy endpoint of time to first asthma
exacerbation19. Rates of asthma exacerbations were secondary
endpoints in the MezzoTinA-, GraziaTinA-, PensieTinA-, RubaTinA-,
VivaTinA- and CanoTinA-asthma trials in adults, adolescents and
children aged 6–11 years with symptomatic asthma. As such, the
individual trials were not powered to assess asthma exacerbations,
given the anticipated and ultimately small proportion of patients
who experienced exacerbations14,17,18,36–38.
DEFINING ASTHMA EXACERBATIONS AND WORSENINGS
Across the five trials in adults with symptomatic asthma and four
trials in paediatric patients aged 6–17 years, ‘asthma worsening’
was defined as an episode of progressive increase in ≥1 asthma
symptom(s) (as compared with usual day-to-day asthma symp-
toms), or a decline of ≥30% in morning PEF (PEFa.m.) for ≥2
consecutive days14,17,18,36–38. ‘Asthma exacerbation’ was defined
as an episode of asthma worsening requiring systemic corticos-
teroids for ≥3 days (Table 1)14,17,18,36–38. The number of patients
with asthma worsenings includes all patients who had asthma
exacerbations.
AEs related to exacerbations and symptoms were used as an
alternative endpoint in the four clinical trials in paediatric patients
aged 6–17 years and the one trial in patients aged 1–5 years
(NinoTinA-asthma). AEs were recorded among safety assessments
in the UniTinA-asthma clinical trials and assigned to specific
MedDRA 18.1 preferred terms39,40. These preferred terms have
previously been described41. Those related to asthma exacerba-
tions and asthma-related symptoms were grouped into an
alternative efficacy endpoint, thus giving an indication of
worsening of disease or exacerbations36,37,39,40,42–47. Szefler
et al.29 previously demonstrated that using AEs related to
exacerbations and symptoms as endpoints was aligned to using
exacerbations as an endpoint, and that it was possible to detect
treatment differences with AE reporting when exacerbation data
were not available.
EXACERBATIONS IN ADULTS WITH SYMPTOMATIC SEVERE
ASTHMA
Tiotropium was shown to significantly reduce the risk of experiencing
at least one asthma exacerbation in adults with symptomatic severe
asthma compared with placebo (hazard ratio [HR] 0.79; 95% confidence
interval [CI] 0.62, 1.00; P= 0.0343) (Fig. 2)19,42.
WORSENINGS IN ADULTS WITH ASTHMA ACROSS SEVERITIES
When pooled, the PrimoTinA-asthma studies were sufficiently
powered to assess the secondary endpoint of time to first asthma
worsening. Tiotropium 5 µg per day was shown to significantly
increase the time to first episode of asthma worsening compared
with placebo (HR 0.69; 95% CI 0.58, 0.82; P < 0.001) (Figs 3, 4)19.

































































Fig. 2 Time to first asthma exacerbation (PrimoTinA-asthma)19. A Kaplan–Meier curve of adults with symptomatic severe asthma receiving
either tiotropium 5 µg once daily or placebo who reported at least one asthma exacerbation over the 48-week trial period. From ref. Kerstjens
et al.19. Copyright © 2012 Massachusetts Medical Society. Reprinted with permission.
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secondary endpoint in the two pooled MezzoTinA-asthma trials
and the GraziaTinA-asthma trial (Fig. 4). Tiotropium 5 µg showed
no significant reduction in the risk of asthma worsenings in
patients with symptomatic moderate or mild asthma compared
with placebo (HR 0.87; 95% CI 0.69, 1.09 and HR 0.58; 95% CI 0.29,
1.16, respectively). Tiotropium 2.5 µg per day, however, provided a
significant reduction in the risk of asthma worsenings in patients
with symptomatic moderate asthma in the MezzoTinA-asthma
trials (HR 0.66; 95% CI 0.52, 0.84), but no significant reduction in
patients with symptomatic mild asthma in the GraziaTinA-asthma
trial (HR 0.96; 95% CI 0.53, 1.75) compared with placebo20,36. The
MezzoTinA-asthma study authors did not elaborate on potential
explanations for why tiotropium 2.5 µg provided a reduction in
the risk of asthma worsenings, but not tiotropium 5 µg. It is worth
noting that for the MezzoTinA- and GraziaTinA-asthma trials,
investigators were unable to calculate the time to first asthma
worsening, as <50% of patients in each treatment group had one
or more incidence of asthma worsening. Therefore, there is a need
for larger trials of longer duration to fully assess the potential
effects of tiotropium on asthma worsenings.
In a systematic review and meta-analysis, Sobieraj et al.22
compared the effect of tiotropium add-on therapy in reducing risk
of asthma worsenings with that of LABA add-on therapy. The
authors pooled data from the adult and adolescent trials in severe
asthma (PrimoTinA and PensieTinA-asthma) and moderate and
mild asthma (MezzoTinA-, GraziaTinA- and RubaTinA-asthma).
When pooled, the data suggest that tiotropium significantly
reduces the risk of asthma worsenings when added to ICS alone
(MezzoTinA-, GraziaTinA-, and RubaTinA-asthma: risk ratio, 0.81,
95% CI 0.68, 0.97) and when added to ICS and additional controller
therapies (PrimoTinA- and PensieTinA-asthma: risk ratio 0.78, 95%
CI 0.72, 0.86). The reduction in risk was reported to be comparable
to that provided by LABA as add-on to ICS.
Fig. 4 Improvements in time to first episode of asthma worsening in patients in the PrimoTinA-, MezzoTinA- and GraziaTinA-asthma
trials receiving tiotropium add-on therapy compared with placebo. Comparison of number of adults with asthma receiving either
tiotropium (5 or 2.5 µg) or placebo once-daily reporting at least one episode of asthma worsening. The vertical axis represents an equal risk of
experiencing an episode of asthma worsening when receiving either placebo or tiotropium. HR values <1 demonstrate that tiotropium
provides a reduction in risk compared with placebo. An upper CI of <1 demonstrates that the reduction in risk is statistically significant. CI










































































Fig. 3 Time to first episode of asthma worsening (PrimoTinA-asthma)19. A Kaplan–Meier curve of adults with symptomatic severe asthma
receiving either tiotropium 5 µg once daily or placebo who reported at least one episode of asthma worsening over the 48-week trial period.
From ref. 19. Copyright © 2012 Massachusetts Medical Society. Reprinted with permission.
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SEASONALITY OF ASTHMA EXACERBATIONS AND
WORSENINGS IN ADULTS
Data from the placebo group of the two PrimoTinA-asthma trials
have provided further evidence of the autumn and winter peaks
of asthma worsenings in adults with symptomatic severe asthma.
Although the exact cause of the peaks was not specified (e.g. if
they were attributable to allergens or viral infections), the
PrimoTinA-asthma trials have demonstrated that, when episodes
were plotted by month, tiotropium 5 µg add-on treatment
reduced the number of episodes of asthma worsenings in adults
with symptomatic severe asthma compared with placebo across
all seasons, but especially during the autumn peak (Fig. 5)48.
Patients were recruited and commenced the 48-week treatment
period across all months of the year, so this observation was not
attributable to duration of treatment19.
WORSENINGS IN PAEDIATRIC PATIENTS AGED 6–17 YEARS
Tiotropium 5 µg per day generally reduced the risk of asthma
worsening in paediatric patients aged 6–17 years with sympto-
matic moderate or mild asthma (HRs 0.60–0.82), although changes
were not statistically significant (Fig. 6a)29. Tiotropium 2.5 µg
per day also provided numerical reductions in the risk of asthma
worsenings in patients aged 6–17 years in the PensieTinA- and
CanoTinA-asthma trials, and statistically significant improvements
in the VivaTinA-asthma trial29. As with the trials in adults with
symptomatic moderate and mild asthma, <50% of patients in
each treatment group had one or more incidence of asthma
worsening29, therefore suggesting the need for larger trials of
longer durations. These results are in line with those reported by
Vogelberg et al.23 in a recent literature review of three add-on
therapies including tiotropium, where the authors reported
significant variability in the design of LABA and LTRA studies in
paediatric patients aged 4–17 years, and noted no difference in
the risk of exacerbations requiring oral corticosteroids (OCS)
between LABAs and LTRA plus ICS compared with ICS alone. The
authors reported that tiotropium provided improvements in time
to first exacerbation requiring OCS when added to ICS vs. placebo.
AES RELATED TO PAEDIATRIC ASTHMA EXACERBATIONS AND
SYMPTOMS
Using a composite endpoint in the five UniTinA-asthma clinical
trials in paediatric patients aged 1–17 years, which has been
demonstrated to be aligned to using exacerbations as an
endpoint29, there was a reduction in the number of paediatric
patients reporting AEs related to asthma exacerbations and
symptoms following treatment with tiotropium 5 µg compared
with placebo. This reduction was significant when data were
pooled (rate ratio 0.76; 95% CI 0.63, 0.93) (Fig. 6b)29. Although
pooling of the data allows for a greater number of patients to be
analysed, thereby providing greater power, it should be noted
that the pooled analysis includes children of different age groups
and asthma severities, and therefore not all data may have been
comparable. When making clinical decisions, data from the
appropriate age group and asthma severity should also be
considered.
SEASONALITY IN PAEDIATRIC PATIENTS WITH ASTHMA
Pooled data from the placebo groups of the PensieTinA-,
RubaTinA-, VivaTinA-, CanoTinA- and NinoTinA-asthma trials
demonstrate seasonal peaks in AEs related to exacerbations and
symptoms during the spring and autumn months. As with the
PrimoTinA-asthma trials, the causes of these peaks are not
specified, but data from the tiotropium add-on therapy groups
demonstrate that both tiotropium 5 and 2.5 µg reduced these
peaks in paediatric patients and could, therefore, represent an
additional intervention for the prevention of seasonal and
predictable peaks in AEs relating to asthma exacerbations and
symptoms (Fig. 7)40,41.
CONCLUSIONS
The definitions of asthma exacerbations and asthma worsenings
often vary across different trials, making the comparison of
outcomes across multiple clinical trials and studies difficult. By
using common definitions throughout the UniTinA-asthma clinical
trial programme, it was demonstrated that tiotropium 5 µg is
effective in reducing asthma exacerbations and worsenings in
adult patients with symptomatic severe asthma. In adults with
mild to moderate-severe asthma, tiotropium 5 µg provided a non-
significant improvement in the time to first episode of asthma
worsening compared with placebo, and in symptomatic moderate
asthma, tiotropium 2.5 µg provided a significant improvement. In
the five UniTinA-asthma trials in paediatric patients, which
analysed exacerbations as a safety endpoint, tiotropium provided
significant reductions in the number of patients aged 1–5 years
with persistent asthmatic symptoms reporting AEs relating to
asthma exacerbations and symptoms compared with placebo.
Evidence was limited for the clinical benefit of tiotropium on
asthma worsenings or improvements in the number of patients
Fig. 5 Number of episodes of asthma worsening by season in patients within the two PrimoTinA-asthma trials48. Number of adult patients
with symptomatic severe asthma reporting at least one episode of asthma worsening receiving either tiotropium 5 µg once daily or placebo
plotted by month. Data from the Southern Hemisphere were shifted by 6 months (July=Month 1, January=Month 7) to align the seasonal
time periods based on meteorological definitions. Patients were recruited and commenced the 48-week treatment period across all months of
the year. From ref. 48. Copyright © 2020. Reprinted with permission.
J Mark FitzGerald et al.
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aged 6–17 years reporting AEs relating to asthma exacerbations
and symptoms compared with placebo. The reduction in
exacerbations with tiotropium was apparent across all patients
during the observed seasonal peaks of these events.
Reporting summary
Further information on experimental design is available in the
Nature Research Reporting Summary linked to this paper.
0.1 1.0 10.0
Trial name Total patients 
treated, N
Treatment arm Patients reporting AEs 
related to asthma and 
exacerbations, n(%) 
symptoms




392 Placebo 28 (20.7)
Tiotropium 5 µg 20 (15.4) 0.71 (0.40, 1.26)
Tiotropium 2.5 µg 23 (18.1) 0.86 (0.49, 1.49)
RubaTinA-
asthma
397 Placebo 48 (34.8)
Tiotropium 5 µg 40 (29.9) 0.83 (0.54, 1.26)
Tiotropium 2.5 µg 50 (40.0) 1.28 (0.86, 1.90)
VivaTinA-
asthma
400 Placebo 51 (38.1)
Tiotropium 5 µg 40 (30.8) 0.73 (0.49, 1.11)
Tiotropium 2.5 µg 37 (27.2) 0.61 (0.40, 0.94)
CanoTinA-
asthma
401 Placebo 70 (53.4)
Tiotropium 5 µg 68 (50.4) 0.89 (0.64, 1.24)
Tiotropium 2.5 µg 73 (54.1) 0.97 (0.70, 1.34)
NinoTinA-
asthma
101 Placebo 20 (58.8)
Tiotropium 5 µg 9 (29.0) 0.35 (0.16, 0.76)
Tiotropium 2.5 µg 12 (33.3) 0.41 (0.20, 0.85)
Pooled studies 1,691 Placebo 217 (37.9)
Tiotropium 5 µg 177 (31.6) 0.76 (0.63, 0.93)




Favours otropium Favours placebo
(b)
RR (95% CI)
Favours otropium Favours placebo
Trial name Total patients 
treated, N
Treatment arm Patients with 
worsening, n(%)
Hazard ratio vs placebo (95% confidence interval)
PensieTinA-
asthma
392 Placebo 25 (18.5)
Tiotropium 5 µg 15 (11.5) 0.60 (0.32, 1.14)
Tiotropium 2.5 µg 18 (14.2) 0.75 (0.41, 1.38)
RubaTinA-
asthma
397 Placebo 37 (26.8)
Tiotropium 5 µg 30 (22.4) 0.82 (0.51, 1.33)
Tiotropium 2.5 µg 34 (27.2) 1.04 (0.65, 1.66)
VivaTinA-
asthma
400 Placebo 47 (35.1)
Tiotropium 5 µg 35 (26.9) 0.69 (0.44, 1.06)
Tiotropium 2.5 µg 29 (21.3) 0.52 (0.33, 0.82)
CanoTinA-
asthma
401 Placebo 66 (50.4)
Tiotropium 5 µg 57 (42.2) 0.77 (0.54, 1.10)
Tiotropium 2.5 µg 63 (46.7) 0.88 (0.62, 1.24)
Fig. 6 Paediatric patients reporting asthma worsenings and adverse events related to asthma exacerbations or symptoms29. Comparison
of number of patients aged 1–17 years with asthma or persistent asthmatic symptoms receiving either tiotropium (5 or 2.5µg) or placebo once
daily reporting (a) asthma worsenings or (b) AEs related to asthma exacerbations or symptoms. The vertical axis represents an equal risk of
experiencing an AE related to asthma exacerbations or symptoms when receiving either placebo or tiotropium. HR/RR values <1 demonstrate
that tiotropium provides a reduction in risk compared with placebo. An upper CI of <1 demonstrates that the reduction in risk is statistically
significant. AE adverse event, CI confidence interval, HR hazard ratio, RR rate ratio. Figure b is from ref. 29. Copyright © 2018. Reprinted with
permission.
J Mark FitzGerald et al.
8
npj Primary Care Respiratory Medicine (2020)    38 Published in partnership with Primary Care Respiratory Society UK
Received: 4 October 2019; Accepted: 18 June 2020;
REFERENCES
1. Pavord, I. D. et al. The impact of poor asthma control among asthma patients
treated with inhaled corticosteroids plus long-acting beta2-agonists in the United
Kingdom: a cross-sectional analysis. NPJ Prim. Care Respir. Med. 27, 17 (2017).
2. Papaioannou, A. I. et al. Control of asthma in real life: still a valuable goal? Eur.
Respir. Rev. 24, 361–369 (2015).
3. Global Initiative for Asthma. Global strategy for asthma management and pre-
vention (2020 report). https://ginasthma.org/wp-content/uploads/2020/04/GINA-
2020-full-report_-final-_wms.pdf (2020).
4. Camargo, C. A. Jr., Rachelefsky, G. & Schatz, M. Managing asthma exacerbations in
the emergency department: summary of the National Asthma Education and
Prevention Program Expert Panel Report 3 guidelines for the management of
asthma exacerbations. J. Allergy Clin. Immunol. 124, S5–S14 (2009).
5. McKeever, T. et al. Quadrupling inhaled glucocorticoid dose to abort asthma
exacerbations. N. Engl. J. Med. 378, 902–910 (2018).
6. Loymans, R. J., Ter Riet, G. & Sterk, P. J. Definitions of asthma exacerbations. Curr.
Opin. Allergy Clin. Immunol. 11, 181–186 (2011).
7. FitzGerald, J. M. & Sadatsafavi, M. Improving precision in the prediction of asthma
exacerbations. Lancet Respir. Med. 5, 539–540 (2017).
8. Fuhlbrigge, A., Bengtsson, T., Peterson, S., Jauhiainen, A. & Fageras, M. CompEx—
a novel composite asthma exacerbation endpoint. Eur. Respir. J. 46, OA3258
(2015).
9. Balter, M. et al. Asthma worsenings: approaches to prevention and management
from the Asthma Worsenings Working Group. Can. Respir. J. 15, 1B–19B (2008).
10. Fuhlbrigge, A. et al. Asthma outcomes: exacerbations. J. Allergy Clin. Immunol.
129, S34–S48 (2012).
11. Dougherty, R. H. & Fahy, J. V. Acute exacerbations of asthma: epidemiology,
biology and the exacerbation-prone phenotype. Clin. Exp. Allergy 39, 193–202
(2009).
12. FitzGerald, J. M. Targeting lung attacks. Thorax 66, 365–366 (2011).
13. Virchow, J. C. et al. Defining moderate asthma exacerbations in clinical trials
based on ATS/ERS joint statement. Respir. Med. 109, 547–556 (2015).
14. Hamelmann, E. et al. Tiotropium add-on therapy in adolescents with moderate
asthma: a 1-year randomized controlled trial. J. Allergy Clin. Immunol. 138,
441–450.e448 (2016).
15. Hamelmann, E. et al. A randomised controlled trial of tiotropium in adolescents
with severe symptomatic asthma. Eur. Respir. J. 49, 1601100 (2017).
16. Vrijlandt, E. J. L. E. et al. Safety and efficacy of tiotropium in children aged 1–5
years with persistent asthmatic symptoms: a randomised, double-blind, placebo-
controlled trial. Lancet Respir. Med. 6, 127–137 (2018).
17. Vogelberg, C. et al. Tiotropium add-on therapy improves lung function in children
with symptomatic moderate asthma. J. Allergy Clin. Immunol. Pract. 6, 2160–2162.
e9 (2018).
18. Szefler, S. J. et al. A phase III randomized controlled trial of tiotropium add-on
therapy in children with severe symptomatic asthma. J. Allergy Clin. Immunol.
140, 1277–1287 (2017).
19. Kerstjens, H. A. et al. Tiotropium in asthma poorly controlled with standard
combination therapy. N. Engl. J. Med. 367, 1198–1207 (2012).
20. Kerstjens, H. A. et al. Tiotropium or salmeterol as add-on therapy to inhaled
corticosteroids for patients with moderate symptomatic asthma: two replicate,
double-blind, placebo-controlled, parallel-group, active-comparator, randomised
trials. Lancet Respir. Med. 3, 367–376 (2015).
21. Paggiaro, P. et al. The effect of tiotropium in symptomatic asthma despite low- to
medium-dose inhaled corticosteroids: a randomized controlled trial. J. Allergy
Clin. Immunol. Pract. 4, 104–113.e2 (2016).
22. Sobieraj, D. M. et al. Association of inhaled corticosteroids and long-acting
muscarinic antagonists with asthma control in patients with uncontrolled, per-
sistent asthma: a systematic review and meta-analysis. JAMA 319, 1473–1484
(2018).
23. Vogelberg, C. et al. A comparison of tiotropium, long-acting β2-agonists and
leukotriene receptor antagonists on lung function and exacerbations in paedia-
tric patients with asthma. Respir. Res. 21, 19 (2020).
24. Thomas, A., Lemanske, R. F. Jr & Jackson, D. J. Approaches to stepping up and
stepping down care in asthmatic patients. J. Allergy Clin. Immunol. 128, 915–924
(2011).
25. Boehringer Ingelheim Limited. Spiriva Respimat 2.5 microgram, inhalation solu-
tion. https://www.medicines.org.uk/emc/product/407/smpc (2018).
26. Boehringer Ingelheim Pharmaceuticals Inc. SPIRIVA® RESPIMAT® (tiotropium
bromide) inhalation spray, for oral inhalation. https://www.accessdata.fda.gov/
drugsatfda_docs/label/2017/021936s007lbl.pdf (2019).
27. Cabana, M. D., Kunselman, S. J., Nyenhuis, S. M. & Wechsler, M. E. Researching
asthma across the ages: insights from the National Heart, Lung, and Blood
Institute’s Asthma Network. J. Allergy Clin. Immunol. 133, 27–33 (2014).
28. Coffey, M. J., Wilfond, B. & Ross, L. F. Ethical assessment of clinical asthma trials
including children subjects. Pediatrics 113, 87–94 (2004).
29. Szefler, S. et al. Improvements in reporting of asthma exacerbations in efficacy
and safety data with tiotropium add-on therapy in pediatric patients. Pediatr.
Pulmonol. 53, S103–S104 (2018).
30. Staton, T. L. et al. Seasonal variability of severe asthma exacerbations and clinical
benefit from lebrikizumab. J. Allergy Clin. Immunol. 139, 1682–1684.e3 (2017).
31. Johnston, N. W. & Sears, M. R. Asthma exacerbations. 1: Epidemiology. Thorax 61,
722–728 (2006).
32. DuBuske, L., Newbold, P., Wu, Y. & Trudo, F. Seasonal variability of exacerbations
of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.


































Winter Spring Summer Autumn
Tiotropium 5 µg Tiotropium 2.5 µg Placebo
Fig. 7 Seasonality of AEs related to asthma exacerbations and symptoms in paediatric patients within the PensieTinA-, RubaTinA-,
VivaTinA-, CanoTinA- and NinoTinA-asthma trials41. Number of patients aged 1–17 years with asthma or persistent asthmatic symptoms
receiving either tiotropium (5 or 2.5 µg) or placebo once daily reporting AEs related to asthma exacerbations and symptoms plotted by
month. Data from the Southern Hemisphere were shifted by 6 months (July=Month 1, January=Month 7) to align the seasonal time periods
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